- Press releases - 06.04.2020
Electronic Death Certificates to Improve Accuracy of COVID-19 Mortality Figures
In order to obtain accurate mortality figures on the COVID-19 pandemic, the data provided by the various entities authorized to issue death certificates – health care establishments, community doctors, emergency medical service (SAMU), and care homes for the elderly – need to be collected quickly. The widespread deployment of electronic death certification made possible by Inserm through its CertDc application should enable rapid acquisition of the figures needed, in order to improve monitoring of the pandemic.
- Press releases - 03.04.2020
Health and environmental crises: a CNRS- Inserm joint initiative
The CNRS and Inserm, in association with the CPU, INED, INRAE and IRD, under the umbrella of ATHENA and AVIESAN1, are joining forces to raise key scientific questions on health and environmental crises and combine the initiatives of the humanities, social sciences and public health research communities arising from the current COVID-19 crisis.
- Press releases - 02.04.2020
Publication of a study in the journal The Lancet Infectious Diseases, covering the first five cases of Covid-19 identified in France and in Europe, between 24 and 29 January 2020
The teams of the Infectious and Tropical Diseases Hospital Bichat AP-HP and the University Hospital of Bordeaux, in collaboration with researchers from University of Paris, Inserm IAME UMRS-1137 (University of Paris / INSERM / University Sorbonne Paris Nord), the Institut Pasteur, the Hospices Civils de Lyon, CNRS – UMR 5308, Ecole Normale Supérieure de Lyon and University Claude Bernard Lyon, published a study based on the monitoring of the first five patients diagnosed Covid-19, admitted to Bichat hospital and the University hospital of Bordeaux.
- Press releases - 01.04.2020
The BCG vaccine against COVID-19 – really?
There has been a lot of talk over the past few days that the BCG tuberculosis virus is a promising ally in the war against COVID-19. But is this actually the case?
- Press releases - 31.03.2020
For diabetic patients confined during the Covid 19-epidemic, the AP-HP, in partnership with Inserm and University of Paris, launches CoviDIAB, a national application for information, prevention and support online
The AP-HP, the Federation of Diabetological Hospital Service and the AP-HP Connected Health Responsibility Centre offer this week to diabetic patients confined at home during the Covid-19 outbreak, a national programme of information, prevention and support for their health.
- Press releases - 27.03.2020
Deploying Cellphone Data to Fight COVID-19
Inserm has joined forces with telecommunications company Orange to study the impact of confinement on population mobility and explore how using aggregated cellphone data could improve COVID-19 pandemic predictions.
- Press releases - 23.03.2020
Exploring the Brain to Clarify the Link Between Sleep Disorders and Alzheimer’s Disease
Sleep disorders have a harmful impact on our brain and under certain conditions are thought to be linked to an increased risk of Alzheimer’s disease. A link which had until now been poorly understood by the scientific community. For the first time, a study based on multiple brain imaging techniques has revealed, among other forms of impairment, the appearance of amyloid plaques characteristic of Alzheimer’s disease in the brains of older adults with sleep apnea but no cognitive disorders.
- What's on? - 23.03.2020
“Fake news” and misinformation around the SARS-CoV2 coronavirus
[/credits] As with all highly mediatized topics, SARS-CoV-2 has its share of misinformation. Originating in the Chinese province of Hubei in 2019, the epidemic caused by this novel coronavirus, now referred to as SARS-CoV-2, and COVID-19 for the disease it causes in people, continues to stoke the fires of not just the traditional media, but […]
- Press releases - 22.03.2020
Launch of a European clinical trial against COVID-19
A European clinical trial to evaluate four experimental treatments for COVID-19 starts this weekend. Coordinated by Inserm as part of the Reacting consortium, this trial will include at least 800 French patients with severe forms of COVID-19.
- Press releases - 20.03.2020
A Mushroom to the Rescue of Patients with Rare Genetic Diseases
An ordinary edible mushroom could be a game-changer when it comes to the treatment of rare genetic diseases. These affect hundreds of millions of people worldwide who often find themselves powerless in the absence of effective therapy. A team of researchers has shown that an active ingredient contained in the Lepista inversa mushroom has repair properties, making it possible to correct certain genetic mutations, known as “nonsense” mutations.